HAINS MYCOBACTERIUM TUBERCULOSIS FIRST AND SECOND LINE DRUG RESISTANCE PROFILE
MRP - ₹ 6,600
What is a HAINS MYCOBACTERIUM TUBERCULOSIS FIRST AND SECOND LINE DRUG RESISTANCE PROFILE?
The **HAINS Mycobacterium Tuberculosis First and Second Line Drug Resistance Profile** is an advanced molecular diagnostic test that detects genetic mutations in *Mycobacterium tuberculosis* associated with resistance to both first-line drugs (like rifampicin and isoniazid) and second-line drugs (such as fluoroquinolones and aminoglycosides). Using line probe assay technology, it provides rapid and accurate identification of multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB strains. This test is performed to guide clinicians in tailoring effective treatment regimens, improving patient outcomes, and preventing the spread of resistant tuberculosis.
Additional Information
| Also known as/ Other names: | TB First & Second Line Drug Resistance Test, Mycobacterium Tuberculosis Drug Resistance Line Probe Assay, MDR/XDR TB Resistance Molecular Panel |
| Parameters: | 1 |
| Recommended for: | M/F/Others |
| Sample Type: | Positive Culture Growth |
| Patient Preparation: | No prior preparation is needed |
| Reports: | Next Saturday |
FAQs
It indicates TB bacteria carry mutations making them resistant to specific drugs, requiring alternative treatment strategies.
It suggests no detectable resistance mutations, meaning standard TB drugs may be effective.
Patients with suspected TB, especially those not responding to treatment or at risk of drug resistance, should undergo this test.
Yes, it identifies resistance to rifampicin and isoniazid, the two key drugs defining multidrug-resistant TB.
Yes, it also detects resistance to second-line drugs like fluoroquinolones and aminoglycosides, confirming extensively drug-resistant TB.
Yes, resistance to key drugs requires alternative regimens, as standard therapy may not work.
Certainly, rapid detection of resistant strains helps doctors adjust treatment quickly, reducing transmission risk.
